Gilead's recent financial reports - any implications for jobs?

Just went through the latest earnings call transcript and financial reports for Gilead. While they're touting some successes, there are also areas that seem a bit shaky, especially with some of the older revenue streams. I'm not a finance expert by any means, but I'm trying to read between the lines. Does anyone who follows the company's financials more closely see anything that might signal a need for cost-cutting down the line? It's not about layoffs specifically, but more about how financial performance might influence future organizational structure or resource allocation. Trying to gauge the overall health and direction. Any thoughts from folks who have been through similar cycles at biotech companies would be appreciated.